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Abstract
After nephron-sparing surgery (NSS), postsurgical fatty tumor could be mistakenly reported as angiomyolipoma during radiologic imaging of 
some patients. In the present paper, we studied the postsurgical fatty tumor detected after NSS but not covered before in the literature. In addi-
tion, we also evaluated whether the postsurgical fatty tumor was related to the surgical technique employed. Patients admitted to the urology 
department of our university hospital from 2014 to 2019 and operated with open NSS were evaluated retrospectively. We detected those 156 
patients were operated with NSS. Nine patients with angiomyolipoma as primary pathology and four patients with surgical border positivity 
were excluded from the study. The patients were divided into two groups based on the repair of tumor extraction region. In Group 1, fatty tissue 
was used for repair, and Group 2 is the primary repair group. In all, 143 patients (Group 1 = 79, and Group 2 = 64) were included in the study. 
No demographic and radiologic differences, such as number of patients, age, gender, positioning of tumor, mass localization, tumor diameter, 
and RENAL nephrometry scoring system, were detected between the two groups. Postsurgical fatty tumors were detected in 28 patients in 
Group 1 and in two patients in Group 2 (P < 0.001). In patients with negative surgical margins after partial nephrectomy, lesions that were 
radiologically detected mimicking as angiomyolipoma were defined as “postsurgical fatty tumor.” This mass containing adipose tissue only nei-
ther depicted vascularization and enhancement nor increase in size for at least 1 year. We assumed that these lesions must be followed as benign 
lesions not requiring additional treatment.
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Renal cell carcinomas (RCC) constitute 90–95% of the 
masses detected in the kidneys. RCCs are the third most 
common malignancy among urogenital tumors (1). Their 
prevalence has increased in Europe as well as globally in the 
last 20 years. The treatment comprises complete or partial 
surgical resection of the kidney (2). While all renal masses 
Balasar M et al.
 Journal of Kidney Cancer and VHL 2022; 9(1): 1–8  2
were treated with radical nephrectomy in the past, presently, 
partial nephrectomy has become the first option for treat-
ing renal masses. Initially, this technique was applied only 
in treating renal masses measuring less than 4 cm; however, 
nephron-sparing surgery (NSS) is used even in case of renal 
masses measuring more than 7 cm (3-5). According to the 
European Association of Urology (EAU) guidelines, NSS 
planning is suggested for treating all suitable T1a masses (6). 
Open, laparoscopic, and robotic application are the modes 
applied for partial nephrectomy. Many studies have demon-
strated similar oncologic results for all three approaches. The 
main principle is to remove the mass altogether, leaving the 
maximal capacity of normal parenchymal tissues without 
any remaining tumoral tissues (7-10).
Methods such as wedge resection and enucleation are 
applied based on experience of the surgeon. After complete 
removal of mass, the opening is repaired primarily or by 
placing fat tissue or hemostatic agents, such as Surgicel and 
spongostan, to control bleeding (11).
Angiomyolipomas (AMLs) are considered as benign renal 
masses. In the past, these were considered hamartoma, but 
presently, these are formed by a heterogeneous tumor group. 
They generally contain fat, muscle, and vascular tissues (12). 
Although all AMLs are perivascular epithelioid cell tumors, 
most present different pathologies, imaging characteristics, 
and clinical behaviors. Since most AMLs contain a signifi-
cant amount of fatty tissue, they are generally diagnosed 
using computed tomography (CT) or magnetic resonance 
imaging (MRI) by defining the imaging characteristics of 
fatty tissues in the mass (13). Although AMLs, which are 
high in fat and can be diagnosed through imaging, are called 
“classic AMLs,” recent developments have presented them as 
different types of renal AMLs. For example, it is known that, 
in addition to classic AMLs, some triphasic AMLs, known 
as low-fat AMLs, contain only a small amount of fatty 
cells and are sometimes mistaken for kidney cancers (14). 
The term “postsurgical fatty tumor” was not reported ear-
lier in the literature. We defined this term as benign lesions 
that contain fatty tissues only and mimic AMLs in radio-
logic imaging, possibly because of repair with fatty tissue in 
the nephrectomy region in patients who underwent partial 
nephrectomy; however, these are not real AMLs.
Postsurgical fatty tumor is reported in imaging of some 
patients after NSS. Our aim in this study was to share infor-
mation about the postsurgical fatty tumor that we detected 
after NSS but was not dealt with before in the literature. 
Further, we evaluated whether it was related to the applied 
surgical technique.
Materials and Methods
Patients admitted to our urology polyclinic with different 
complaints or pre-diagnosis of renal mass between 2014 and 
2021 were evaluated. They were applied open NSS following 
detection of renal mass. A total of 156 patients had partial 
nephrectomy. Nine patients with AMLs as primary pathol-
ogy and four patients with surgical border positivity were 
excluded from the study. In all, 143 patients were included 
in the study.
After complete examination, findings such as complaints 
of patients at hospital admittance, presence of additional 
disease, preoperative mass dimension and localization, oper-
ative time, bleeding amount, duration of hospitalization, and 
pathology results were recorded. Contrasted abdomen CT 
(CACT) of all the included patients was taken preoperatively 
to evaluate renal mass. All patients also had thorax CT for 
preoperative staging. 
RENAL nephrometry scoring system was used to decide 
surgical intervention. Pre- and postoperative hemogram and 
biochemistry measures were recorded and compared between 
two groups. All patients were divided into risk groups for 
routine control of 15 days after discharge. Postoperative fol-
low-up protocol was evaluated as mentioned in EAU guide-
lines (15). 
The follow-up protocol of the American Urological Asso-
ciation (AUA) and/or EAU guidelines was used for patient 
population (15, 16). Postoperative evaluation in low-risk 
patients was performed with ultrasonography (USG) in the 
6th month, CACT in the 12th month, USG in the 2nd year, 
and CACT in the 3rd year. Average- and high-risk patients 
were evaluated with CACT in 6th, 12th, 24th, and 36th 
postoperative months. Patients with benign pathology were 
evaluated with USG in the 6th postoperative month. All 
USG and CACT findings of postoperative follow-ups of the 
patients were recorded.
The local human research ethics committee (Necmettin 
Erbakan University, Meram Medical Faculty Ethics Com-
mittee) approved the protocol “2015/236.” The analysis and 
data collection were performed following the Declaration of 
Helsinki after written informed consent was obtained from 
all patients.
Surgical technique
Surgery was conducted under general anesthesia applied to all 
patients. Wedge resection or enucleation was planned based 
on preference of the surgeon or condition of the patient. The 
peritoneum was entered after anterior subcostal incision on 
the operation side. The descending or ascending colon was 
dissected based on positioning of tumor; the colon was freed 
through dissection, and the retroperitoneal area was reached 
after medialization. Gerota fascia and perirenal fatty tissue 
were completely dissected from the kidney and excised. Fatty 
tissue on the mass was excised and sent to pathology. Warm 
ischemia was performed on patients based on either tumor 
size and RENAL nephrometry scoring system or preference 
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observed. The patients were discharged after removal of 
catheters. They were called for routine control and follow-up 
in the 2nd week of discharge.
Definition of Postsurgical Fatty Tumor
Patients who did not have AMLs as primary pathology and 
had negative surgical border following partial nephrectomy 
were also defined for lesions detected radiologically and 
mimicking as AMLs. Such patients included fatty tissue only, 
did not present vascularization and contrasting, and had no 
dimensional increase in a minimum of 1-year follow-up. The 
radiologic image of postsurgical fatty tumor is presented in 
Figure 2.
Statistical Analysis
Dataset analyses were made using the Statistical Package for 
Social Sciences volume 23.0 (IBM Corp., IL, Chicago). Con-
tinuous variables were presented as mean values and stan-
dard deviations. Independent t-test and Mann–Whitney U 
test were used for analyzing two groups. The Chi-square (χ2) 
test was applied for relationship analysis between categoric 
variables. P < 0.05 was accepted as statistically significant.
Results
Partial nephrectomy was applied after retrospective data 
scanning in 143 patients. No difference was detected between 
of the surgeon, or the surgery was completed without isch-
emia application. In ischemia-applied patients, surgical pro-
cedure was applied with the ischemia duration of less than 
20 minutes. Tumor tissue was completely removed with 2–3-
mm normal tissue from the border in patients applied wedge 
resection. In enucleation, the mass was completely removed 
by excising from pseudo capsule border through blunt dissec-
tion. The patients were divided into the following two groups 
based on the repair of tumor extraction region. 
Group 1. Group in which fatty tissue was used for repair: 
It was prepared by wrapping as a roll with Surgicel around 
the fatty tissue taken from the non-tumoral area. Fatty tissue 
wrapped with hemostatic agent (SURGICEL®, Johnson & 
Johnson, Somerville, NJ), prepared in advance, was located 
in the opening and the tumor was removed from this area. 
The opening was closed with 2/0 absorbable suture. The tech-
nique applied is presented in Figure 1.
Group 2. Primary repair group: The opening where the 
tumor was removed was first closed with 3/0 absorbable 
suture and afterward with 2/0 absorbable suture. Surgicel 
and/or fibrin gel (FLOSEAL, Baxter Healthcare, Fremont, 
CA) was used as a hemostatic agent without using fatty tis-
sue to stop bleeding between the sutures.
In either of the mentioned techniques, a catheter was 
placed in the perirenal area after control of bleeding, and 
the surgery ceased by suturing the layers in anatomic plane. 
Findings such as operative time and bleeding amount were 
recorded. Catheters placed in all the patients were removed 
on postoperative day 1, and spontaneous diuresis was 
Figure 1: Perirenal adipose tissue taken from the non-tumoral area (left); appearance after the Surgicel is wrapped around the 
adipose tissue (middle); Surgicel-wrapped adipose tissue that was used for defect repair (right).
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Figure 2: Image of postsurgical fatty tumor through contrast abdomen computed tomography.
the two groups regarding demographic and radiologic 
parameters such as the number of patients, age, gender, posi-
tioning of tumor, mass localization, tumor diameter, and 
RENAL nephrometry scoring system. Demographic and 
radiologic parameters of the groups are provided in Table 1. 
Pathology of 119 patients (83.2%) in the entire patient 
population was detected as malign. The mean operative time 
was 101.3 ± 14.4 min (75–145 min), and the mean bleed-
ing amount was measured as 263.9 ± 147.6 cc (50–750 cc). 
The median follow-up time was determined as 32 months 
(13–95 months). Evaluation of laboratory, preoperative, 
and postoperative parameter results of both groups demon-
strated no significant difference other than the presence of 
postsurgical fatty tumor. Postsurgical fatty tumor in Group 
1 was detected in 28 patients (35.4%), in which fat tissue 
was used for repair. In Group 2, the primary repair group, 
postsurgical fatty tumor was detected in just two patients 
(3.12%) (P < 0.001). In addition, a positive correlation was 
observed between the presence of postsurgical fatty tumor 
and the surgical technique used for fat tissue to repair (P < 
0.001). Laboratory, preoperative, and postoperative results 
of both groups are provided in Table 2. It was observed that 
in the following period distant metastasis developed in four 
patients (2.8%). In addition, local relapse was observed in 
four patients (2.8%) during the follow-up period. There was 
no difference in metastasis and relapse rates between the 
both groups (P = 0.831 and P = 0.325).
It was observed radiologically that the postsurgical fatty 
tumor in the nephrectomy region included fatty tissue only, 
and lacked vascularization and contrast involvement. No 
increase was observed in the mass size of detected postsur-
gical fatty tumor following a minimum of 1-year follow-up.
Discussion
The use of NSS has risen by eight times in the last 20 years. 
It is used in 90% of T1a renal tumors (17). Enucleation and 
wedge resection are used as NSS methods. In both surgical 
methods different techniques and materials are used in renal 
defect area to cover collecting system and renal parenchyma 
and prevent postoperative bleeding following tumor resec-
tion (18). Urlesberger et al. stated that fibrin glues were used 
in renal parenchymal surgery (19). Levinson et al. reported 
providing successful hemostasis using fibrin glues in seven 
patients to repair following partial nephrectomy (20). Sim-
ilarly, in a review, Ito et al. reported successful hemostasis 
with fibrin glues (21). Gill et al. compared Surgicel with the 
combination of gelatin matrix thrombin sealant (FLOSEAL, 
Baxter Healthcare, CA) for repair after laparoscopic partial 
nephrectomy. The authors stated that the use of combination 
was effective in lowering nonhemostatic complications(22) 
due to complete biocompatibility and feeding being per-
formed through osmosis and not blood vessels (23). In the 
beginning, the kidney opening and closure technique is 
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Table 1: Demographic and radiologic parameters of the groups.
Variables Group 1 Group 2 P-value
Number of patients 79 64

























Tumor diameter (mm) 38.2 (±15.1) 41.1 (±16.9) 0.281
Renal score 5.2 (±1.3) 4.9 (±1) 0.107
Follow-up time (months) 34.6 (±17.4) 36.7 (±19.9) 0.104
employed by locating the Surgicel-wrapped fatty tissue in 
the defective area of kidney parenchyma after tumor resec-
tion. Use of fatty tissue prevents urinary leakage, provides 
successful hemostasis, and a tension-free repair. Özkan et 
al. called this technique “lipocorticoplasty” in a study pub-
lished in 2011 (24). We had applied repair with fatty tissue 
in 79 patients and fatty tissue-free repair in 64 patients. We 
observed no difference in oncologic results between the tech-
niques. Similar bleeding amount and operation period were 
observed in both groups. During postoperative evaluation, 
we observed appearance of postsurgical fatty tumor in 28 
(35.4%) patients in Group 1 using fatty tissue, and in just two 
patients (3.12%) in Group 2, primary repair group, not using 
fatty tissue for repair. These findings made us contemplate 
that AMLs reported during postoperative period were not 
actual AMLs but radiologically reported AMLs because of 
the fatty tissue used during surgery. We called them as post-
surgical fatty tumor. 
Angiomyolipomas are benign renal masses. Their prev-
alence changes approximately between 0.3% and –5% (25). 
They are defined as benign masses that generally have 
slow and uniform growth and cause minimal morbidity. 
Although 80% have a sporadic appearance and are unim-
portant, nearly 20% are related to tuberosclerosis. They can 
be detected randomly and may also cause clinical manifes-
tations such as life-threatening bleeding (26). Histologically, 
renal AML can be classified as typical and atypical. Typical 
AMLs are triphasic and contain all three components in 
different proportions, namely, dilated blood vessels (angio), 
smooth muscle cells (myo), and mature adiposities (lipo). 
These three tissues are considered to develop from the same 
stem cell. Most AMLs belong to this group. However, some 
tumors consist of almost exclusively one component, while 
others are present in very small amounts. They are called 
monophasic AMLs, for example, the epitheloid variants 
of AMLs. Epitheloid AMLs contain no or very little fatty 
tissue. They generally contain numerous epithelioid muscle 
cells with abundant eosinophilic and granular cytoplasm. 
They may have aggressive local progress and present malign 
transformation. Histologically, they may be mistaken for 
RCC (27). Some authors claimed that renal AMLs could be 
classified radiologically through CT and MRI findings. They 
were classified as high-, low-, and no-fat AMLs based on the 
amount of fat detected in imaging studies (28). In literature, 
postsurgical fatty tumor was not reported in any definition.
We defined these lesions as postsurgical fatty tumor 
because they consisted of only fatty tissue and did not con-
tain smooth muscle and vascular tissues. They are mistakenly 
reported as AMLs in postoperative period.
These findings make us believe that appearance of post-
surgical fatty tumor is related to the fatty tissue located 
in the region because of the applied surgical technique. 
Although the employed surgical method has advantages, 
such as shorter operation duration, although statistically 
insignificant, misdiagnosis of AMLs during postoperative 
period is a primary disadvantage. However, we assumed that 
these lesions were not real AMLs but mistakenly reported as 
AMLs due to their highly fatty radiologic image. While most 
AMLs were followed up through active imaging, those caus-
ing clinical manifestations like pain or having bleeding risk 
must be treated. Treatment must also be planned in case of 
AMLs measuring more than 4–5 cm due to bleeding risk (12, 
29). On the contrary, vascularization was not observed in the 
detected postsurgical fatty tumor. No increase was observed 
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regarding their dimensions during follow-up. No additional 
treatment was required due to lack of vascularization, con-
trast involvement, or increase in dimensions. 
Its higher prevalence in Group 1, using fatty tissue for 
repair, with appearance of postsurgical fatty tumor is a dis-
advantage of this technique. In the patients of Group 2 (pri-
mary repair group), in which fatty tissue was not used for 
repair, we believe the present image appeared due to other 
hemostatic agents used independently of fatty tissue. 
Postsurgical fatty tumor appears as benign lesions not 
requiring additional treatment in evaluating masses detected 
postoperatively in patients who had partial nephrectomy 
and whose pathology was not reported as AMLs. We believe 
Table 2: Laboratory, preoperative, and postoperative results of the groups.
Variables Group 1 Group 2 P-value
Preop. hemoglobin (gm/dL) 14.3 (±1.7) 13.7 (±1.9) 0.051
Preop. creatinine (mg/dL) 0.88 (±0.23) 0.94 (±0.46) 0.145
Bleeding (mL) 254.2 (±140.9) 276.1 (±155.7) 0.379
Operation time (min) 99.7 (±15.2) 103.2 (±13.2) 0.146
Ischemia time (min) 14.8 (±2.3) 15.3 (±2) 0.074
Postop. hemoglobin (gm/dL) 12.6 (±1.9) 12.5 (±1.8) 0.75






























































that postsurgical fatty tumor must be evaluated in distinc-
tive diagnosis for evaluating these masses. Defined masses 
are observed in the partial nephrectomy region, free from 
postsurgical pathology. We believe that they are not actual 
AMLs, although they are generally diagnosed as AMLs in 
radiologic terms and appear like postsurgical fatty tumor as 
lipomatous tissue, probably because of the materials, such as 
fatty tissue, used during surgery. 
Conclusion
In patients with negative surgical margins after partial 
nephrectomy, lesions detected radiologically were defined as 
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postsurgical fatty tumors. They contained only adipose tis-
sue, and neither depicted vascularization and enhancement 
nor increase in size for at least 1 year. We believe that these 
lesions must be followed up as benign lesions, not requiring 
additional treatment.
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